Anti-Human CD37 Reference Antibody (BI 836826, RUO) (HY564076)

Name: Anti-Human CD37 Reference Antibody (BI 836826, RUO)
Brand: abinScience
SKU: HY564076
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY564076
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Clonality	Monoclonal
Isotype	IgG
Clone ID	BI 836826
Expression system	Mammalian cells
Target	CD37, Tspan-26, TSPAN26, Leukocyte antigen CD37, Tetraspanin-26
Endotoxin level	< 10 EU/mg
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P11049
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	BI-836826, BI836826, BI836826
Background	Leukocyte antigen CD37 (TSPAN26) is a ~31 kDa protein. Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling. Participates thereby in diverse biological functions such as cell signal transduction, adhesion, migration and protein trafficking. Upon ligand binding, two signaling pathways are activated, one acting through phosphorylation by LYN leading to cell death or a survival pathway with activation of GSK3B. Plays an essential role essential for clustering of integrin ITGA4/ITGB1 and promotes its mobility in the plasma membrane of B-cells. In turn, participates in ITGA4/ITGB1 integrin-mediated antiapoptotic signaling through AKT. 1. Lapalombella, R. et al. (2012) Cancer cell 21, 694-708. PMID: 22624718 2. de Winde, CM. et al. (2016) The Journal of clinical investigation 126, 653-66. PMID: 26784544 3. Meyer-Wentrup, F. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 178, 154-62. PMID: 17182550
References	1. Deborah M Stephens DO, et al. BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia. Blood. Volume 124, Issue 21, 6 December 2014, Page 4681. [HY564076]
Note	For research use only. Not suitable for clinical or therapeutic use.